Neonatal isoerythrolysis

Last updated

Neonatal isoerythrolysis (NI), also known as hemolytic icterus or hemolytic anemia, [1] is a disease most commonly seen in kittens and foals, but has also been reported in puppies. It occurs when the mother has antibodies against the blood type of the newborn.

Contents

A 7 day old foal with neonatal isoerythrolysis. Djaenisse moultea.JPG
A 7 day old foal with neonatal isoerythrolysis.

Neonatal isoerythrolysis in kittens

In cats, the antibodies are already present in the queen's blood before parturition. The blood group antigens are similar in structure to the antigen of a common bacteria in the gut of cats leading to antibody formation. Kittens obtain the majority of their immune response from the colostrum, and are not born with a strong immune response. When they absorb the mother's antibodies against their blood type it causes lysis of the red blood cells leading to anemia. Symptoms include lethargy, weakness, depression, pale mucus membranes, fever, and blood in the urine. Hypoxia may lead to forebrain disease, increased heart rate and respiratory rate, and liver or kidney disease. Animals suffering from this disease must be taken to a veterinarian immediately. Treatment includes fluid support and blood transfusions. The condition is most commonly seen in kittens with type-A blood born to mothers with type-B blood since type-B cats form very strong anti-type A antibodies. The condition is less common (and less severe) in type-B kittens born to type-A mothers.

It can be prevented by blood typing the mother and kittens. If there is a blood-type mismatch, the kittens should not be allowed to nurse for 72 hours from the mother to prevent the passage of antibodies in the colostrum. After that, the kittens can be allowed to nurse naturally. [2]

Neonatal isoerythrolysis in foals

Neonatal isoerythrolysis usually presents during the first 4 days of a foal's life, [2] or 4-7 days in mule foals. It is a medical emergency and requires immediate veterinary attention to prevent further decline in health and subsequent death.

Pathophysiology

Neonatal isoerythrolysis occurs if a foal is born with a blood group that is different from its dam, and then receives antibodies against those red blood cells (alloantibodies) through the mare's colostrum, leading to the lysis of the foal's red blood cells. There are thus three requirements for this disease to occur:

  1. The foal must inherit and express an antigen from the stallion's blood group that is not present in the mare.
  2. The mare must have already produced alloantibodies against this antigen, which can only occur if she has been previously exposed to the incompatible red blood cells prior to birth of the foal.
  3. The foal must ingest these alloantibodies through the colostrum of the mare when the gut is still "open" (able to absorb antibodies, the first 24 hours following birth). [2]

The first scenario for the mare's exposure occurs if she is bred to a stallion of incompatible blood group, and during foaling receives the foal's red blood cells into her circulation due to transplacental hemorrhage. [2] Because of the delay in production of antibody, this first foal is not at risk for isoerythrolysis since the mare will not have circulating antibodies until after colostrum production has ceased, meaning this foal will never have a chance for exposure. However, subsequent foals that are by the same stallion or a different stallion that carries the same incompatible blood group, are at risk, and as such this disease is most commonly seen in foals out of multiparous mares. Additionally, exposure can occur due to placental abnormalities in early gestation that allow the foal's red blood cells to leak into the mare's circulation, or if the mare is exposed through blood transfusion. [2] Because this exposure occurs well before the foal receives colostrum, the mare will have circulating antibodies at the time of parturition and therefore the foal is at risk of developing NI.

During the final month of gestation, alloantibodies concentrate into the colostrum. Horses, unlike humans, have an epitheliochorial placenta which prevents the transfer of antibodies to the foal in-utero. Foals are only exposed when they first nurse and ingest colostrum, so therefore are born without the disease and acquire it soon after birth. After ingestion, these antibodies coat the red blood cells of the foal, leading to lysis through the complement system or removal by the mononuclear phagocyte system, and causing subsequent anemia. [2]

Blood groups associated with neonatal isoerythrolysis

Most blood groups do not produce a highly immunologic response when the mare is exposed from previous foals or through placental leakage of red blood cells. However, a few factors, such as Aa and Qa, do lead to a significant response and therefore account for the majority of cases of isoerythrolysis. Mares that are Aa- and Qa-negative are therefore most likely to produce a foal with this condition. This is most commonly seen in Thoroughbreds (19%) and Arabians. [2] Additionally, mule foals are especially at risk due to an associated donkey factor. Immune mediated thrombocytopenia often occurs concurrently in mule foals suffering from neonatal isoerythrolysis. [2]

Some mares have natural alloantibodies, usually to the Ca blood group, without ever having a known exposure to that blood group. This is seen in 10% of Thoroughbred mares and 20% of Standardbred mares. [2] In this case, Ca alloantibodies are thought to actually suppress a response against Aa blood groups, and therefore these mares do not make Aa alloantibodies if the foal has both Ca positive and Aa positive blood. These natural alloantibodies have not been shown to produce isoerythrolysis in foals, and are actually thought to help prevent NI by desensitization of the immune system and preventing the more harmful Aa alloantibodies from forming. [2]

Alloantibodies against De, Ua, Pa, and Ab blood groups have also been associated with neonatal isoerythrolysis. [2]

Clinical signs and testing

Icteric mucous membranes seen in a mule foal with NI. Djaenisse moultea ouy.JPG
Icteric mucous membranes seen in a mule foal with NI.

Foals present normally at birth, but over the following 12–72 hours [2] weaken, become depressed, and have a decreased suckle response. Signs typical of hemolytic anemia occur, including tachycardia (increased heart rate), tachypnea (increased respiratory rate), dyspnea, pale mucosa which becomes icteric by 24–48 hours of age, and occasionally hemoglobinuria. In more severe cases, seizures may occur secondary to cerebral hypoxia. Laboratory findings will show a decreased packed cell volume (PCV) that is usually less than 20%, [2] an increased bilirubin, especially unconjugated bilirubin, and occult blood in the urine.

A definitive diagnosis can only be made if alloantibodies are discovered in the mare's serum or colostrum and are shown to be against the foal's red blood cells. Such tests include crossmatching the mare's serum to washed red blood cells of the foal, which is added to exogenous complement, and is positive if hemolysis occurs. A direct Coombs test may also be used, but does have a high rate of false negatives. Crossmatching using saline agglutination does run the risk of false negatives, since some alloantibodies only produce lysis rather than agglutination. Currently, screening tests of colostrum for use in the field have not been found to be accurate. [2]

The severity of clinical signs and their speed of onset is determined by the dose of alloantibodies taken in by the foal and their potency. Alloantibodies against the Aa blood group are especially potent, and usually produce more severe signs than other alloantibodies when an equivalent dose is absorbed. Mares with multiple exposures to a blood group antigen also produce a greater amount of alloantibodies and therefore the foal receives a larger dose. [2]

Treatment and prognosis

If diagnosed prior to time of gut closure (foal is less than 24 hours of age), the foal should be given an alternative nutrient source via nasogastric tube. The mare should be stripped of milk and the foal muzzled during the time to prevent additional ingestion of colostrum. However, this disease is usually diagnosed in foals greater than 24 hours of age, in which case the foal is safe to continue to ingest the mother's milk. Foals are supported with fluids, which are used to maintain hydration, correct electrolyte and acid-base imbalances, and help perfuse the stressed kidneys which can be damaged by the circulating hemoglobin. Foals are kept warm and as quiet as possible, and exercise is limited. Intranasal oxygen may be used to improve blood oxygen levels. Antimicrobials are also sometimes given to help prevent sepsis, which is more likely to occur in a compromised foal. [2]

Blood transfusion is indicated if PCV drops below 12%,. [2] The mare's blood may be used for transfusion if the red blood cells are washed multiple times to remove the serum component containing antibodies. If the mare can not be used, an alternative donor that is Aa and Qa negative may be used. This donor profile is most commonly seen in Quarter Horses, Morgans, and Standardbreds and is less likely in Thoroughbreds and Arabians, [2] but ideally the donor should be blood typed prior to use rather than using breed as the sole method of identification. [2] In mule foals, female donors that have been previously bred to a jack should not be used. Transfusion usually consists of 2-4 L of blood, or 1-2 L of packed cells, over the course of 2–4 hours. [2] Blood transfusion is not without risks: these cells stress the mononuclear phagocytic system, increasing the foal's risk of infection, and also may lead to future transfusion reactions, so transfusion should only occur if required to save the animal's life. [2] In the rare case where a suitable donor is not available or hemoglobin levels drop below 5 mg/dl, polymerized bovine hemoglobin may be given. [2] PCV declines 4–7 days after initial transfusion. [2] Dexamethasone is also sometimes used, but can affect blood glucose regulation of the patient. [2]

Prognosis depends on the amount of alloantibody received and their potency, which may be indirectly measured by the degree of clinical signs. Some cases may result in a dead foal before diagnosis can be made. If there is slow onset of signs, supportive care often is enough to keep the foal alive. [2]

Prevention

After producing a foal with NI, a mare is more likely to do so again. In this case, all subsequent foals should be given an alternative source of colostrum unless the mare is blood typed and bred to a compatible stallion. [2] In breeds most commonly associated with this disease, such as Thoroughbreds and Arabians, compatible stallions that fit with the goals of the breeder's program may be difficult to find. If a non-compatible stallion is used, the mare's serum should be tested for alloantibodies in the final month of gestation. Those with alloantibodies should be stripped of colostrum at the time of parturition, and foals should be given an alternative source. Mares with alloantibodies to the Ca blood group are not at risk for producing neonatal isoerythrolysis in foals, and may be at decreased risk for NI in their foals (see above), so do not need an alternative colostrum source provided to their foals if the foal is Ca positive. Blood groups that have been associated with NI, such as Ab, De, Ua, and Pa, are generally not used in risk assessment of mares. [2]

See also

Related Research Articles

<span class="mw-page-title-main">Blood type</span> Classification of blood based on antibodies and antigens on red blood cell surfaces

A blood type is a classification of blood, based on the presence and absence of antibodies and inherited antigenic substances on the surface of red blood cells (RBCs). These antigens may be proteins, carbohydrates, glycoproteins, or glycolipids, depending on the blood group system. Some of these antigens are also present on the surface of other types of cells of various tissues. Several of these red blood cell surface antigens can stem from one allele and collectively form a blood group system.

Rh disease is a type of hemolytic disease of the fetus and newborn (HDFN). HDFN due to anti-D antibodies is the proper and currently used name for this disease as the Rh blood group system actually has more than 50 antigens and not only the D-antigen. The term "Rh Disease" is commonly used to refer to HDFN due to anti-D antibodies, and prior to the discovery of anti-Rho(D) immune globulin, it was the most common type of HDFN. The disease ranges from mild to severe, and occurs in the second or subsequent pregnancies of Rh-D negative women when the biologic father is Rh-D positive.

<span class="mw-page-title-main">Hemolytic disease of the newborn</span> Fetal and neonatal alloimmune blood condition

Hemolytic disease of the newborn, also known as hemolytic disease of the fetus and newborn, HDN, HDFN, or erythroblastosis fetalis, is an alloimmune condition that develops in a fetus at or around birth, when the IgG molecules produced by the mother pass through the placenta. Among these antibodies are some which attack antigens on the red blood cells in the fetal circulation, breaking down and destroying the cells. The fetus can develop reticulocytosis and anemia. The intensity of this fetal disease ranges from mild to very severe, and fetal death from heart failure can occur. When the disease is moderate or severe, many erythroblasts are present in the fetal blood, earning these forms of the disease the name erythroblastosis fetalis.

Alloimmunity is an immune response to nonself antigens from members of the same species, which are called alloantigens or isoantigens. Two major types of alloantigens are blood group antigens and histocompatibility antigens. In alloimmunity, the body creates antibodies against the alloantigens, attacking transfused blood, allotransplanted tissue, and even the fetus in some cases. Alloimmune (isoimmune) response results in graft rejection, which is manifested as deterioration or complete loss of graft function. In contrast, autoimmunity is an immune response to the self's own antigens. Alloimmunization (isoimmunization) is the process of becoming alloimmune, that is, developing the relevant antibodies for the first time.

In ABO hemolytic disease of the newborn maternal IgG antibodies with specificity for the ABO blood group system pass through the placenta to the fetal circulation where they can cause hemolysis of fetal red blood cells which can lead to fetal anemia and HDN. In contrast to Rh disease, about half of the cases of ABO HDN occur in a firstborn baby and ABO HDN does not become more severe after further pregnancies.

Hemolytic disease of the newborn (anti-Kell1) is the second most common cause of severe hemolytic disease of the newborn (HDN) after Rh disease. Anti-Kell1 is becoming relatively more important as prevention of Rh disease is also becoming more effective.

Hemolytic disease of the newborn (anti-Rhc) can range from a mild to a severe disease. It is the third most common cause of severe HDN. Rh disease is the most common and hemolytic disease of the newborn (anti-Kell) is the second most common cause of severe HDN. It occurs more commonly in women who are Rh D negative.

The term human blood group systems is defined by the International Society of Blood Transfusion (ISBT) as systems in the human species where cell-surface antigens—in particular, those on blood cells—are "controlled at a single gene locus or by two or more very closely linked homologous genes with little or no observable recombination between them", and include the common ABO and Rh (Rhesus) antigen systems, as well as many others; 44 human systems are identified as of December 2022.

The Kell antigen system is a human blood group system, that is, a group of antigens on the human red blood cell surface which are important determinants of blood type and are targets for autoimmune or alloimmune diseases which destroy red blood cells. The Kell antigens are K, k, Kpa, Kpb, Jsa and Jsb. The Kell antigens are peptides found within the Kell protein, a 93-kilodalton transmembrane zinc-dependent endopeptidase which is responsible for cleaving endothelin-3.

<span class="mw-page-title-main">Rh blood group system</span> Human blood group system involving 49 blood antigens

The Rh blood group system is a human blood group system. It contains proteins on the surface of red blood cells. After the ABO blood group system, it is the most likely to be involved in transfusion reactions. The Rh blood group system consisted of 49 defined blood group antigens in 2005. As of 2023, there are over 50 antigens among which the five antigens D, C, c, E, and e are the most important. There is no d antigen. Rh(D) status of an individual is normally described with a positive (+) or negative (−) suffix after the ABO type. The terms Rh factor, Rh positive, and Rh negative refer to the Rh(D) antigen only. Antibodies to Rh antigens can be involved in hemolytic transfusion reactions and antibodies to the Rh(D) and Rh antigens confer significant risk of hemolytic disease of the newborn.

Animal erythrocytes have cell surface antigens that undergo polymorphism and give rise to blood types. Antigens from the human ABO blood group system are also found in apes and Old World monkeys, and the types trace back to the origin of humanoids. Other animal blood sometimes agglutinates with human blood group reagents, but the structure of the blood group antigens in animals is not always identical to those typically found in humans. The classification of most animal blood groups therefore uses different blood typing systems to those used for classification of human blood.

Neonatal alloimmune thrombocytopenia is a disease that affects babies in which the platelet count is decreased because the mother's immune system attacks her fetus' or newborn's platelets. A low platelet count increases the risk of bleeding in the fetus and newborn. If the bleeding occurs in the brain, there may be long-term effects.

<span class="mw-page-title-main">Ii antigen system</span> Human blood group system

The Ii antigen system is a human blood group system based upon a gene on chromosome 6 and consisting of the I antigen and the i antigen. The I antigen is normally present on the cell membrane of red blood cells in all adults, while the i antigen is present in fetuses and newborns.

Hemolytic disease of the newborn (anti-RhE) is caused by the anti-RhE antibody of the Rh blood group system. The anti-RhE antibody can be naturally occurring, or arise following immune sensitization after a blood transfusion or pregnancy.

Type II hypersensitivity, in the Gell and Coombs classification of allergic reactions, is an antibody mediated process in which IgG and IgM antibodies are directed against antigens on cells or extracellular material. This subsequently leads to cell lysis, tissue damage or loss of function through mechanisms such as

  1. complement activation via the classical complement pathway
  2. Antibody-dependent cellular cytotoxicity or
  3. anti-receptor activity.

An acute hemolytic transfusion reaction (AHTR), also called immediate hemolytic transfusion reaction, is a life-threatening reaction to receiving a blood transfusion. AHTRs occur within 24 hours of the transfusion and can be triggered by a few milliliters of blood. The reaction is triggered by host antibodies destroying donor red blood cells. AHTR typically occurs when there is an ABO blood group incompatibility, and is most severe when type A donor blood is given to a type O recipient.

This page is currently under construction.

An Intrauterine transfusion (IUT) is a procedure that provides blood to a fetus, most commonly through the umbilical cord. It is used in cases of severe fetal anemia, such as when fetal red blood cells are being destroyed by maternal antibodies. IUTs are performed by perinatologists at hospitals or specialized centers.

<span class="mw-page-title-main">Blood compatibility testing</span> Testing to identify incompatibilities between blood types

Blood compatibility testing is conducted in a medical laboratory to identify potential incompatibilities between blood group systems in blood transfusion. It is also used to diagnose and prevent some complications of pregnancy that can occur when the baby has a different blood group from the mother. Blood compatibility testing includes blood typing, which detects the antigens on red blood cells that determine a person's blood type; testing for unexpected antibodies against blood group antigens ; and, in the case of blood transfusions, mixing the recipient's plasma with the donor's red blood cells to detect incompatibilities (crossmatching). Routine blood typing involves determining the ABO and RhD type, and involves both identification of ABO antigens on red blood cells and identification of ABO antibodies in the plasma. Other blood group antigens may be tested for in specific clinical situations.

<span class="mw-page-title-main">Monocyte monolayer assay</span> Laboratory test for clinically significant alloantibodies

The monocyte monolayer assay (MMA) is used to determine the clinical significance of alloantibodies produced by blood transfusion recipients. The assay is used to assess the potential for intravascular hemolysis when incompatible cellular blood products are transfused to the anemic patient. When donor cells possess substances that are not produced by the recipient, the recipient's immune system produces antibodies against the substance; these are called alloantibodies. Specific white blood cells, called monocytes, are tasked with ingesting foreign material and become activated during certain inflammatory events. These activated monocytes come in contact with antibody-sensitized red blood cells (RBC) and may or may not exhibit phagocytosis (ingestion) and destroy the donor red blood cells. If monocytes destroy the RBC, the antibody attached to those RBC is considered clinically significant.

References

  1. ↑ Eldredge, Debra M.; Carlson, Delbert G.; Carlson, Liisa D.; Giffin, James M. (2008). Cat Owner's Home Veterinary Handbook. Howell Book House. p. 469.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Reed, Stephen M., Waewick M. Bayly, and Debra C. Sellon. (2010). Equine Internal Medicine (Third ed.). St Louis, MO: Saunders. pp. 1336–1337. ISBN   978-1-4160-5670-6.{{cite book}}: CS1 maint: multiple names: authors list (link)

Shaw, SP. Neonatal Isoerthrolysis in Clinical Veterinary Advisor: Dogs and Cats 3rd Ed. Cote, E ed. Elsevier, 2015. p. 698.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.